Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21423210
Dulak AM, et al. (2011) HGF-independent potentiation of EGFR action by c-Met. Oncogene 30, 3625-35 21423210
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
crizotinib HGF inhibit treatment-induced increase
EGF no change compared to control

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
crizotinib HGF inhibit treatment-induced increase
EGF no change compared to control

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
crizotinib HGF inhibit treatment-induced increase
EGF no change compared to control

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
crizotinib HGF inhibit treatment-induced increase
EGF no change compared to control

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
crizotinib HGF inhibit treatment-induced increase
EGF no change compared to control

Y1003-p - Met (human)
Modsite: VsNEsVDyRAtFPED SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1003‑p, Met iso2 (human): Y1021‑p, Met (mouse): Y1001‑p, Met (rat): Y1004‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase at 24-48h
HGF increase at 1-2h

Y1234-p - Met (human)
Modsite: RDMyDkEyysVHNkt SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1234‑p, Met iso2 (human): Y1252‑p, Met (mouse): Y1232‑p, Met (rat): Y1235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase at 24-48h
HGF increase at 1-2h

Y1235-p - Met (human)
Modsite: DMyDkEyysVHNktG SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1235‑p, Met iso2 (human): Y1253‑p, Met (mouse): Y1233‑p, Met (rat): Y1236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase at 24-48h
HGF increase at 1-2h

Y1365-p - Met (human)
Modsite: NVKCVAPyPsLLssE SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1365‑p, Met iso2 (human): Y1383‑p, Met (mouse): Y1363‑p, Met (rat): Y1366‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase at 24-48h
HGF increase at 1-2h

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer
Relevant cell lines - cell types - tissues:  201T ('epithelial, lung'), A549 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase 24-48h